NASDAQ:XNCR

Xencor Stock Insider Trading

Healthcare > Biotechnology

Buy XNCR

*Your capital is at risk

$20.21

-1.28 (-5.96%)

At Close: Jul 31, 2026

Xencor Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be negative at -21.05. In total, the insiders bought 2.63M and sold 313.63K XNCR shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	-21.05
● Buy	2.63M shares
● Sell	313.63K shares
68% Buy Activity Moderate Negative Correlation
Buy Signal Low Confidence Mar 02, 2026 Analysis Breakdown: Signal is highly questionable due to a strongly contradictory negative Insider Power Score of -21.05. Confidence increased due to high data reliability score of 100.

Historical Insider Trades

Date	Type	Person	Role	Amount
Jun 12, 2025 Buy	Common Stock A-Award	Feigal Ellen Director	Director	13 686 Value: $129.1K
Jun 12, 2025 Buy	Stock Option (Right to Buy) A-Award	Simpson Todd E Director	Director	27 372 Value: $258.1K
Jun 12, 2025 Buy	Common Stock A-Award	Simpson Todd E Director	Director	13 686 Value: $129.1K
Jun 12, 2025 Buy	Stock Option (Right to Buy) A-Award	Ranieri Richard J Director	Director	27 372 Value: $258.1K
Jun 12, 2025 Buy	Common Stock A-Award	Ranieri Richard J Director	Director	13 686 Value: $129.1K
Jun 12, 2025 Buy	Common Stock A-Award	Ranieri Richard J Director	Director	13 686 Value: $129.1K
Jun 12, 2025 Buy	Stock Option (Right to Buy) A-Award	Ranieri Richard J Director	Director	27 372 Value: $258.1K
Jun 12, 2025 Buy	Common Stock A-Award	Simpson Todd E Director	Director	13 686 Value: $129.1K
Jun 12, 2025 Buy	Stock Option (Right to Buy) A-Award	Simpson Todd E Director	Director	27 372 Value: $258.1K
Jun 12, 2025 Buy	Common Stock A-Award	Feigal Ellen Director	Director	13 686 Value: $129.1K
Jun 12, 2025 Buy	Stock Option (Right to Buy) A-Award	Feigal Ellen Director	Director	27 372 Value: $258.1K
Jun 12, 2025 Buy	Common Stock A-Award	Gorman Kevin Charles Director	Director	13 686 Value: $129.1K
Jun 12, 2025 Buy	Stock Option (Right to Buy) A-Award	Gorman Kevin Charles Director	Director	27 372 Value: $258.1K
Jun 12, 2025 Buy	Common Stock A-Award	Gustafson Kurt A Director	Director	13 686 Value: $129.1K
Jun 12, 2025 Buy	Stock Option (Right to Buy) A-Award	Gustafson Kurt A Director	Director	27 372 Value: $258.1K
Jun 12, 2025 Buy	Common Stock A-Award	Klencke Barbara Director	Director	13 686 Value: $129.1K
Jun 12, 2025 Buy	Stock Option (Right to Buy) A-Award	Klencke Barbara Director	Director	27 372 Value: $258.1K
Jun 12, 2025 Buy	Common Stock A-Award	Montgomery Alan Bruce Director	Director	13 686 Value: $129.1K
Jun 12, 2025 Buy	Stock Option (Right to Buy) A-Award	Montgomery Alan Bruce Director	Director	27 372 Value: $258.1K
May 02, 2025 Sell	Common Stock S-Sale	Valente Nancy EVP, Chief Development Officer	Officer	4 616 Value: $50.9K
May 02, 2025 Sell	Common Stock S-Sale	Valente Nancy EVP, Chief Development Officer	Officer	4 616 Value: $50.9K
Apr 10, 2025 Sell	Common Stock S-Sale	Cornelissen Bart Jan Sr. Vice President & CFO	CEO / President	3 750 Value: $30.2K
Apr 10, 2025 Sell	Common Stock S-Sale	Cornelissen Bart Jan Sr. Vice President & CFO	CEO / President	3 750 Value: $30.2K
Mar 13, 2025 Buy	Stock Option (Right to Buy) A-Award	Simpson Todd E Director	Director	43 337 Value: $557.7K
Mar 13, 2025 Buy	Common Stock J-Other	Simpson Todd E	Director	0 Value: $0

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT XENCOR

Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with r...

Read Full Profile Here